1 Min Read
April 24 (Reuters) - American Regent:
* American Regent announces enrollment of first patient in phase 3 trial to investigate injectafer (ferric carboxymaltose) as treatment for heart failure with iron deficiency Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.